Intervention Protocol

You have free access to this content

Safety of off-label erythropoiesis-stimulating agents for critically ill patients

  1. Bita Mesgarpour1,2,
  2. Benedikt H Heidinger2,
  3. Dominik Roth2,
  4. Susanne Schmitz3,
  5. Cathal D Walsh4,
  6. Harald Herkner2,*

Editorial Group: Cochrane Anaesthesia, Critical and Emergency Care Group

Published Online: 12 FEB 2014

DOI: 10.1002/14651858.CD010969

How to Cite

Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H. Safety of off-label erythropoiesis-stimulating agents for critically ill patients (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010969. DOI: 10.1002/14651858.CD010969.

Author Information

  1. 1

    Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

  2. 2

    Medical University of Vienna, Department of Emergency Medicine, Vienna, Austria

  3. 3

    Trinity College Dublin, Department of Pharmacology & Therapeutics, Dublin, Ireland

  4. 4

    Trinity College Dublin, Department of Statistics, Dublin, Ireland

*Harald Herkner, Department of Emergency Medicine, Medical University of Vienna, Allgemeines Krankenhaus, Währinger Gürtel 18-20,, Vienna, 1090, Austria.

Publication History

  1. Publication Status: New
  2. Published Online: 12 FEB 2014



Additional references

Aher 2012
Bohlius 2009
Bohlius 2012
Brophy 2008
  • Brophy GM, Sheehan V, Shapiro MJ, Lottenberg L, Scarlata D, Audhya P. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit. Clinical Therapeutics 2008;30(12):2324-34. [DOI: 10.1016/j.clinthera.2008.12.024; PUBMED: 19167591]
Chateauvieux 2011
Cody 2005
  • Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003266.pub2; PUBMED: 16034896]
Corwin 2004
  • Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, et al. The CRIT study: anemia and blood transfusion in the critically ill—current clinical practice in the United States. Critical Care Medicine 2004;32(1):39-52. [PUBMED: 14707558]
Corwin 2006
Corwin 2007
  • Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. New England Journal of Medicine 2007;357(10):965-76. [PUBMED: 17804841]
DeAngelo 2005
  • DeAngelo AJ,  Bell DG,  Quinn MW,  Long DE,  Ouellette DR. Erythropoietin response in critically ill mechanically ventilated patients: a prospective observational study. Critical Care 2005;9(3):R172-6. [PUBMED: 15987387]
Egger 1997
FDA 2010
  • FDA: Food, Drug Administration. Information on Erythropoiesis-Stimulating Agents (ESA) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp). Safety Announcement from February 16, 2010. Accessed 23 July 2013.
Fishbane 2010
  • Fishbane S. The role of erythropoiesis-stimulating agents in the treatment of anemia. The American Journal of Managed Care 2010;16(3):S67-S73. [PUBMED: 20297874]
Goldsmith 2010
Guyatt 2008
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
Higgins 2012
  • Higgins J. Convincing evidence from controlled and uncontrolled studies on the lipid-lowering effect of a statin [editorial]. Cochrane Database of Systematic Reviews 2012; Vol. 12, issue 12:ED000049. (accessed 23 July 2013). [DOI: 10.1002/14651858.ED000049; PUBMED: 23361645]
Hobisch-Hagen 2001
  • Hobisch-Hagen P,  Wiedermann F,  Mayr A,  Fries D,  Jelkmann W,  Fuchs D,  et al. Blunted erythropoietic response to anemia in multiply traumatized patients. Critical Care Medicine 2001;29(4):743-7. [PUBMED: 11373460]
Hopewell 2013
  • Hopewell S, Omar O, Hyde C, Yu LM, Doree C, Murphy MF. A systematic review of the effect of red blood cell transfusion on mortality: evidence from large-scale observational studies published between 2006 and 2010. BMJ Open 2013;3(5):e002154. [DOI: 10.1136/bmjopen-2012-002154; PUBMED: 23645909]
Krafte-Jacobs 1994
Lambin 2009
Loke 2007
Maiese 2005
Marik 2008
Martí-Carvajal 2013
  • Martí-Carvajal AJ, Agreda-Pérez LH, Solà I, Simancas-Racines D. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD000332.pub3; PUBMED: 23450527]
Mesgarpour 2013a
  • Mesgarpour B. Search strategies and systematic review/meta-analysis on off-label drug use [PhD thesis]. Vienna: Medical University of Vienna, 2013.
Mesgarpour 2013b
  • Mesgarpour B, Heidinger BH, Schwameis M, Kienbacher C, Walsh, C, Schmitz S, et al. Safety of off-label erythropoiesis stimulating agents in critically ill patients: a systematic review and meta-analysis. Intensive Care Medicine 2013;Aug 9:Epub ahead of print. [DOI: 10.1007/s00134-013-3030-9; PUBMED: 23928897]
Ngo 2010
Palmer 2010
Phrommintikul 2007
  • Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369(9559):381-8. [PUBMED: 17276778]
Prevost 2000
RevMan 5.2 [Computer program]
  • Version 5.2. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rogiers 1997
  • Rogiers P,  Zhang H,  Leeman M,  Nagler J,  Neels H,  Mélot C,  et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Medicine 1997;23(2):159-62. [PUBMED: 9069000]
Rucker 2008
Santaguida 2008
  • Santaguida PL, Raina P. The development of the McHarm Quality Assessment Scale for adverse events: Delphi Consensus on important criteria for evaluating harms, 2008.
Schmitz 2013
Schwarzer 2012 [Computer program]
  • Schwarzer G. Meta-Analysis with R. R package version 2.1-1. CRAN, 2012.
Sutton 2008
Thomas 2006
Tonelli 2009
  • Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. Canadian Medical Association Journal 2009;180(11):E62-71. [DOI: 10.1503/cmaj.090470; PUBMED: 19407261]
Tonia 2012
Vekeman 2006
  • Vekeman F, Lefebvre P, Mody SH, Raut M, McKenzie RS, Watson S, et al. Dosing and transfusion patterns of erythropoietic stimulating therapies in critically ill patients. Critical Care Medicine 2006;34(12):A128.
Vekeman 2007
  • Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, et al. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. American Journal of Health-System Pharmacy 2007;64(18):1943-9. [PUBMED: 17823106]
Walsh 2010
Wells 2009
  • Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses, 2009.
Zarychanski 2007
  • Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal 2007;177(7):725-34. [PUBMED: 17823140]
Zarychanski 2008